Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Placebo for Enzalutamide
Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2013-11-26

Last Posted Date: 2023-09-18

Lead Sponsor: Pfizer

Target Recruit Count: 509

Registration Number: NCT01995513

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇦🇺
Box Hill Hospital, Box Hill, Victoria, Australia
🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Belgium

and more 86 locations

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

Phase 3

Completed

Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy

Interventions: Drug: Placebo
Drug: Tafamidis

First Posted Date: 2013-11-26

Last Posted Date: 2019-04-24

Lead Sponsor: Pfizer

Target Recruit Count: 441

Registration Number: NCT01994889

Locations: 🇺🇸
The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸
UAB Hospital Department of Pharmacy IDS, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Arizona - Mayo Clinic Speciality Building, Phoenix, Arizona, United States

and more 77 locations

A Single Dose Study Of PF-06678552 In Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06678552 or Placebo

First Posted Date: 2013-11-25

Last Posted Date: 2014-03-28

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT01992614

Locations: 🇧🇪
Pfizer Investigational Site, Brussels, Belgium

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

Phase 2

Terminated

Conditions: Macular Edema, Diabetic

Interventions: Drug: Ranibizumab
Drug: PF-04634817
Drug: Masked Sham Therapy
Drug: Placebo

First Posted Date: 2013-11-25

Last Posted Date: 2016-10-17

Lead Sponsor: Pfizer

Target Recruit Count: 199

Registration Number: NCT01994291

Locations: 🇺🇸
Retinal Diagnostic Center, Campbell, California, United States
🇺🇸
Southern California Desert Retina Consultants, Palm Desert, California, United States
🇺🇸
American Institute of Research (Administrative Only), Whittier, California, United States

and more 60 locations

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Biological: PF-05280014
Biological: Herceptin®
Drug: Paclitaxel

First Posted Date: 2013-11-21

Last Posted Date: 2021-07-06

Lead Sponsor: Pfizer

Target Recruit Count: 707

Registration Number: NCT01989676

Locations: 🇺🇦
Municipal Institution Odesa Regional Clinical Hospital, Mammology Center, Odesa, Ukraine
🇺🇦
Municipal Institution "Chernivtsi Regional Clinical Oncology Center", Outpatient Department, Chernivtsi, Ukraine
🇺🇦
Zakarpattia Regional Clinical Oncological Center, Uzhgorod, Ukraine

and more 177 locations

A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma

Phase 2

Completed

Conditions: Advanced Multiple Myeloma

Interventions: Drug: Carfilzomib, proteasome inhibitor; intravenous
Drug: Filanesib, KSP(Eg5) inhibitor; intravenous
Drug: Dexamethasone, steroid; oral or intravenous
Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

First Posted Date: 2013-11-21

Last Posted Date: 2020-09-16

Lead Sponsor: Pfizer

Target Recruit Count: 77

Registration Number: NCT01989325

Locations: 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸
Prairie Lakes Health Care System, Watertown, South Dakota, United States
🇺🇸
Memorial Sloan Kettering, New York, New York, United States

and more 19 locations

A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults

Phase 1

Withdrawn

Conditions: Migraine

Interventions: Drug: Placebo Tablets
Drug: PF-05180999 Tablets

First Posted Date: 2013-11-11

Last Posted Date: 2014-05-23

Lead Sponsor: Pfizer

Registration Number: NCT01981486

A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06649751

First Posted Date: 2013-11-11

Last Posted Date: 2014-03-26

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT01981694

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

Phase 1

Terminated

Conditions: Migraine

Interventions: Drug: 360 mg MR PF-05180999
Drug: 10 mg cetirizine
Drug: Placebo
Drug: PF-05180999
Drug: 120 mg MR PF-05180999

First Posted Date: 2013-11-11

Last Posted Date: 2014-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 31

Registration Number: NCT01981499

Locations: 🇺🇸
Pfizer Investigational Site, St. Paul, Minnesota, United States

A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06263726
Drug: Placebo

First Posted Date: 2013-11-11

Last Posted Date: 2014-07-17

Lead Sponsor: Pfizer

Target Recruit Count: 47

Registration Number: NCT01981681

Locations: 🇧🇪
Pfizer Investigational Site, Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy